{"groups":[{"description":"Participants with symptomatic untreated low grade NHL will be treated according to a 28 day schedule for up to a maximum of 12 consecutive cycles:\n\n375 mg/m\\^2 Rituximab IV on day 1. 20 mg Lenalidomide taken orally on days 1-21.\n\n250 mg/m\\^2 Cyclophosphamide orally on days 1, 8, 15.\n\n40 mg Dexamethasone orally on days 1, 8, 15, 22.","id":"FG000","title":"Treatment"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Cancel Prior to Initiating Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"36"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}